TY - JOUR
T1 - Histologic diversity in chromophobe renal cell carcinoma does not impact survival outcome
T2 - A comparative international multi-institutional study
AU - Kolar, Jiri
AU - Llaurado, Andrea Feu
AU - Ulamec, Monika
AU - Skenderi, Faruk
AU - Perez-Montiel, Delia
AU - Alvarado-Cabrero, Isabel
AU - Bulimbasic, Stela
AU - Sperga, Maris
AU - Tretiakova, Maria
AU - Osunkoya, Adeboye O.
AU - Rogala, Joanna
AU - Comperat, Eva
AU - Gal, Viliam
AU - Dunatov, Ana
AU - Pivovarcikova, Kristyna
AU - Michalova, Kvetoslava
AU - Vesela, Adriena Bartos
AU - Slisarenko, Maryna
AU - Strakova, Andrea Peterikova
AU - Pitra, Tomas
AU - Hora, Milan
AU - Michal, Michal
AU - Alaghehbandan, Reza
AU - Hes, Ondrej
N1 - Funding Information:
The study was supported in part by the Charles University Research Fund (Cooperation Program, research area SURG), the Institutional Research Fund of University Hospital Plzen (Faculty Hospital in Plzen- FNPl 00669806 ).
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/10
Y1 - 2022/10
N2 - Predicting the clinical behavior and trajectory of chromophobe renal cell carcinoma (ChRCC) by histologic features has so far proven to be challenging. It is known that ChRCC represents a heterogeneous group of neoplasms demonstrating variable, yet distinctive morphologic and genetic profiles. In this international multi-institutional study, we aimed to assess the impact of histologic diversity in ChRCC (classic/eosinophilic versus rare subtypes) on survival outcome. This is an international multi-institutional matched case-control study including 14 institutions, examining the impact of histologic subtypes of ChRCC on survival outcome. The study group (cases) included 89 rare subtypes of ChRCC. The control group consisted of 70 cases of ChRCC including classic and eosinophilic features, age- and tumor size-matched. Most of the rare subtypes were adenomatoid cystic/pigmented ChRCC (66/89, 74.2%), followed by multicystic ChRCC (10/89, 11.2%), and papillary ChRCC (9/89, 10.1%). In the control group, there were 62 (88.6%) classic and 8 (11.4%) eosinophilic ChRCC. There were no statistically significant differences between the study and control groups for age at diagnosis, gender distribution, tumor size, presence of tumor necrosis, presence of sarcomatoid differentiation, and adverse outcomes. No statistically significant differences were found in clinical outcome between the rare subtypes and classic/eosinophilic groups by tumor size, necrosis, and sarcomatoid differentiation. Further, no statistically significant differences were found in clinical outcome between the two groups, stratified by tumor size, necrosis, and sarcomatoid differentiation. Our findings corroborated previous studies that both sarcomatoid differentiation and tumor necrosis were significantly associated with poor clinical outcome in classic/eosinophilic ChRCC, and this was proven to be true for ChRCC with rare histologic subtypes as well. This study suggests that rare morphologic patterns in ChRCC without other aggressive features play no role in determining the clinical behavior of the tumor.
AB - Predicting the clinical behavior and trajectory of chromophobe renal cell carcinoma (ChRCC) by histologic features has so far proven to be challenging. It is known that ChRCC represents a heterogeneous group of neoplasms demonstrating variable, yet distinctive morphologic and genetic profiles. In this international multi-institutional study, we aimed to assess the impact of histologic diversity in ChRCC (classic/eosinophilic versus rare subtypes) on survival outcome. This is an international multi-institutional matched case-control study including 14 institutions, examining the impact of histologic subtypes of ChRCC on survival outcome. The study group (cases) included 89 rare subtypes of ChRCC. The control group consisted of 70 cases of ChRCC including classic and eosinophilic features, age- and tumor size-matched. Most of the rare subtypes were adenomatoid cystic/pigmented ChRCC (66/89, 74.2%), followed by multicystic ChRCC (10/89, 11.2%), and papillary ChRCC (9/89, 10.1%). In the control group, there were 62 (88.6%) classic and 8 (11.4%) eosinophilic ChRCC. There were no statistically significant differences between the study and control groups for age at diagnosis, gender distribution, tumor size, presence of tumor necrosis, presence of sarcomatoid differentiation, and adverse outcomes. No statistically significant differences were found in clinical outcome between the rare subtypes and classic/eosinophilic groups by tumor size, necrosis, and sarcomatoid differentiation. Further, no statistically significant differences were found in clinical outcome between the two groups, stratified by tumor size, necrosis, and sarcomatoid differentiation. Our findings corroborated previous studies that both sarcomatoid differentiation and tumor necrosis were significantly associated with poor clinical outcome in classic/eosinophilic ChRCC, and this was proven to be true for ChRCC with rare histologic subtypes as well. This study suggests that rare morphologic patterns in ChRCC without other aggressive features play no role in determining the clinical behavior of the tumor.
KW - Chromophobe renal cell carcinoma
KW - Grading
KW - Kidney
KW - Outcome
KW - Subtypes
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85130458442&partnerID=8YFLogxK
U2 - 10.1016/j.anndiagpath.2022.151978
DO - 10.1016/j.anndiagpath.2022.151978
M3 - Article
C2 - 35609473
AN - SCOPUS:85130458442
SN - 1092-9134
VL - 60
JO - Annals of Diagnostic Pathology
JF - Annals of Diagnostic Pathology
M1 - 151978
ER -